PremiumThe FlyKaryopharm price target adjusted to $10 from $5 at Barclays Karyopharm Therapeutics Reports Q1 2025 Earnings and Clinical Progress Karyopharm reports Q1 EPS ($2.77), consensus ($3.09) PremiumThe FlyKaryopharm price target lowered to split-adjusted $15 from $75 at Piper Sandler Karyopharm price target lowered to $54 from $75 at Baird Karyopharm target adjusted to $7 from $56 at H.C. Wainwright PremiumRatingsKaryopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating Karyopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for Funding Karyopharm’s 2024 Earnings and Clinical Progress 
